| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/JIQ060 |
| P8608 | Fatcat ID | release_yn2xmszvujdcxgqgat3sjrccqy |
| P932 | PMC publication ID | 3071120 |
| P698 | PubMed publication ID | 21208919 |
| P5875 | ResearchGate publication ID | 49731390 |
| P2093 | author name string | Stephen J Thomas | |
| P2860 | cites work | Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections | Q27469477 |
| Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability | Q27477548 | ||
| Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination | Q27486068 | ||
| A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus | Q27486406 | ||
| Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers | Q27486552 | ||
| A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model | Q27490166 | ||
| Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers | Q27490989 | ||
| Dengue virus-induced hemorrhage in a nonhuman primate model | Q27491021 | ||
| Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance | Q27491036 | ||
| Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys | Q27491049 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice | Q28473775 | ||
| Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century | Q29616264 | ||
| In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody | Q29619712 | ||
| Characteristics of dengue fever in a large public hospital, Jeddah, Saudi Arabia. | Q33372667 | ||
| Imported dengue fever in Austria 1990-2005. | Q33373256 | ||
| Dengue hemorrhagic fever--U.S.-Mexico border, 2005. | Q33376194 | ||
| Dengue fever outbreak in Karachi 2006--a study of profile and outcome of children under 15 years of age. | Q33378740 | ||
| Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study | Q33453934 | ||
| Diversity and origin of dengue virus serotypes 1, 2, and 3, Bhutan | Q33836634 | ||
| Report of an NIAID workshop on dengue animal models | Q34058747 | ||
| Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive | Q34088956 | ||
| Dengue epidemiology: virus epidemiology, ecology, and emergence | Q35625026 | ||
| Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. | Q35645556 | ||
| Dengue fever, Hawaii, 2001-2002 | Q35873101 | ||
| Targeted mutagenesis as a rational approach to dengue virus vaccine development | Q36118259 | ||
| Dengue in travelers | Q36246244 | ||
| Development of a live attenuated dengue virus vaccine using reverse genetics | Q36428460 | ||
| Dengue and dengue haemorrhagic fever in Bandung | Q36541400 | ||
| Immunopathological mechanisms in dengue and dengue hemorrhagic fever | Q36581319 | ||
| Economic burden of dengue infections in India | Q37134806 | ||
| Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses | Q37162404 | ||
| Understanding the contribution of cellular immunity to dengue disease pathogenesis | Q37287832 | ||
| Attenuated D2 16681-PDK53 vaccine: defining humoral and cell-mediated immunity | Q37438402 | ||
| A mouse model for studying dengue virus pathogenesis and immune response | Q37596554 | ||
| Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis | Q37608068 | ||
| Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses | Q37609595 | ||
| Development of Sanofi Pasteur tetravalent dengue vaccine | Q37791334 | ||
| Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study | Q38874657 | ||
| Locally acquired Dengue--Key West, Florida, 2009-2010. | Q38935762 | ||
| Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine | Q38938760 | ||
| Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. | Q38947937 | ||
| Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children | Q39417673 | ||
| Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. | Q39417682 | ||
| The health and economic impact of dengue in Latin America | Q39530090 | ||
| Evaluation of interferences between dengue vaccine serotypes in a monkey model. | Q39887927 | ||
| Immunogenicity of sanofi pasteur tetravalent dengue vaccine | Q39942050 | ||
| Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults | Q39955421 | ||
| A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults | Q40369287 | ||
| Recent progress on sanofi pasteur's dengue vaccine candidate | Q40378149 | ||
| Disability adjusted life years lost to dengue in Brazil | Q40398806 | ||
| Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects | Q40410592 | ||
| Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies | Q40414894 | ||
| "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation | Q40415284 | ||
| Sonographic findings of healthy volunteers infected with dengue virus | Q40420430 | ||
| Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. | Q40424733 | ||
| Epidemic dengue and dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based seroepidemiologic survey, December 2005. | Q40424751 | ||
| Dengue and hemorrhagic fever: a potential threat to public health in the United States | Q40429888 | ||
| rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. | Q40464785 | ||
| Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. | Q40468558 | ||
| A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. | Q40475448 | ||
| Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). | Q40480637 | ||
| An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model | Q40504189 | ||
| Technology evaluation: ChimeriVax-DEN, Acambis/Aventis. | Q40524380 | ||
| Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | Q40536052 | ||
| Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates | Q40541513 | ||
| Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines | Q40541517 | ||
| Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. | Q40541524 | ||
| Dengue Fever in travelers returning from southeast Asia. | Q40551278 | ||
| Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. | Q40578159 | ||
| Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. | Q40593118 | ||
| Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine | Q40597033 | ||
| Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines | Q40604094 | ||
| Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques | Q40619965 | ||
| Live attenuated tetravalent dengue vaccine | Q40621161 | ||
| Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein | Q40624173 | ||
| Dengue fever in US military personnel in Haiti | Q40650597 | ||
| Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation | Q40782907 | ||
| Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers | Q40798795 | ||
| Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels. | Q40826131 | ||
| Enhancement of dengue virus infection in monocytes by flavivirus antisera. | Q40860643 | ||
| Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. | Q41019028 | ||
| Experimental studies on dengue. I. Isolation, identification and modification of the virus | Q41051723 | ||
| PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. | Q41092633 | ||
| Antibody-dependent enhancement in dengue virus infections | Q42997718 | ||
| Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum | Q44151722 | ||
| Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. | Q45017668 | ||
| From the Centers for Disease Control and Prevention. Dengue fever at the US-Mexico border, 1995-1996 | Q71748532 | ||
| Dengue surveillance--United States, 1986-1992 | Q72685369 | ||
| From the Centers for Disease Control and Prevention. Dengue fever among U.S. military personnel--Haiti, September-November, 1994 | Q72897638 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| P304 | page(s) | 299-303 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | The necessity and quandaries of dengue vaccine development | |
| P478 | volume | 203 |
| Q36523070 | A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults |
| Q42977513 | An in vitro bioassay for the quantitative evaluation of mosquito repellents against Stegomyia aegypti (=Aedes aegypti) mosquitoes using a novel cocktail meal |
| Q38140035 | Challenges in reducing dengue burden; diagnostics, control measures and vaccines |
| Q36511979 | Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice |
| Q33724565 | Dengue human infection model: introduction |
| Q26314686 | Dengue vaccine: a valuable asset for the future |
| Q55109773 | Dengue-Virus-Infektionen |
| Q34297640 | Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment |
| Q37957502 | Immunization in travel medicine |
| Q26314599 | Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategy |
| Q47549097 | Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo |
| Q34746139 | Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies |
| Q40136145 | Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. |
| Q38202176 | Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop |
| Q38303232 | Recent progress in dengue vaccine development |
| Q35976650 | Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine |
| Q30395028 | Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. |
| Q26860307 | Role of microparticles in dengue virus infection and its impact on medical intervention strategies |
| Q36026210 | Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial |
| Q38232097 | Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. |
| Q36382589 | Sculpting humoral immunity through dengue vaccination to enhance protective immunity |
| Q38032553 | Treatment of dengue fever |
| Q28074355 | Trends in clinical trials of dengue vaccine |
| Q38208436 | Vaccination for the expatriate and long-term traveler |
| Q26314715 | Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies |
Search more.